The Diabetic Drug lawyers at Bohrer Brady, LLC are evaluating cases of ketoacidosis for persons taking the diabetic medicines Invokana (FDA approved March 2013), Invokamet, Farxiga (FDA approved January 2014), Xigduo XR, Jardiance (FDA approved August 2014), and Glyxambi.
CONTACT USThe diabetic prescription medicines Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi are a new type of drug used to treat Type 2 diabetes and are known as sodium glucose cotransporter-2 or SGLT 2 inhibitors. These medications are prescribed to treat adult Type 2 diabetes and are designed to lower blood sugar levels. SGLT 2 drugs lower sugar levels in the body by removing blood sugar through the kidneys.
On May 15, 2015, the FDA issued a warning that Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, and Glyxambi might lead to ketoacidosis. Ketoacidosis is a condition in which the body does not produce enough insulin and begins to break down fat as a source of energy, which results in a buildup of toxic acids in the bloodstream called ketones. An excessive ketone level can result in ketoacidosis. Symptoms of ketoacidosis can include the following:
Possible complications of ketoacidosis include cerebral edema, or fluid buildup around the brain, heart attack, death of bowel tissue due to low blood pressure, and kidney failure.
Heart attacks are caused by a blood clot that blocks one of the coronary arteries. The arteries bring blood and oxygen to the heart. If blood flow is blocked, the heart is deprived of oxygen and heart cells die.
Acute kidney failure is the loss of your kidneys’ ability to remove waste and help balance fluids and electrolytes in your body.
Do you have a diabetes drug claim?
If you or a loved one have experienced any of these side effects associated with your use of Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, or Glyxambi, consult your health care provider immediately.
CONTACT US© 2024 Bohrer Brady Law. All Rights Reserved.St. Louis Internet Marketing by The Clix Group
Online
Phone
